Trials / Completed
CompletedNCT00563524
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
AN ASCENDING MULTIPLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL EFFICACY OF ILV-094 ADMINISTERED SUBCUTANEOUSLY OR INTRAVENOUSLY TO SUBJECTS WITH PSORIASIS
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 76 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess safety, and tolerability of multiple doses of ILV-094 administered to subjects with psoriasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ILV-094 | SC and IV administration on days 1, 14, 28, and 42 |
Timeline
- Start date
- 2007-12-20
- Primary completion
- 2010-06-14
- Completion
- 2010-06-14
- First posted
- 2007-11-26
- Last updated
- 2024-08-23
- Results posted
- 2024-08-23
Locations
24 sites across 4 countries: United States, Canada, Hong Kong, South Africa
Source: ClinicalTrials.gov record NCT00563524. Inclusion in this directory is not an endorsement.